OncoRNA SA is a subsidiary of OncoDNA SA, a leading genomics and theranostics company focused on precision medicine for cancer and genetic diseases. Our mission of OncoRNA is to manufacture and commercialize Personalized RNA Cancer Immuno-Therapy (PRCIT) potentially a fast, high-performant, and cost-effective personalized immunotherapies for cancer patients. Our therapy utilizes a proprietary technology that combines small neoantigen mRNA (snmRNA) pool technology with lipid nanoparticle (LNP) technology, enabling the design of personalized mRNA cancer vaccines. By stimulating the patient's immune system to target and eliminate tumor cells based on specific mutations, OncoRNA's PRCIT offers a groundbreaking approach to cancer immunotherapy.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Rue Louis Breguet 1, Charleroi,walloon Region 6041,belgium
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://oncorna.eu
- HQ
- Charleroi, Walloon Region
Oncorna Questions
Oncorna's website is https://oncorna.eu
Oncorna's LinkedIn profile is https://be.linkedin.com/company/oncorna
Oncorna has
2 employees.
View email and phone details for 2
employees at Oncorna.
Oncorna's industry is
Pharmaceutical Manufacturing
Oncorna's top competitors are
Quantoom Biosciences,
Hemastatx,
Exothera,
Mestastop® Solutions,
Adipopharma Sas,
Immunofusion,
Oncodna,
Signatur Biosciences,
Celyad Oncology,
Stellaris Therapeutics.
Oncorna's categories are Pharmaceutical Manufacturing
Oncorna's founding year is 2023
